Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
|ClinicalTrials.gov Identifier: NCT01929356|
Recruitment Status : Withdrawn (no physiotherapist available for treatment of patients during trial, difficulties with recruitment)
First Posted : August 27, 2013
Last Update Posted : November 24, 2017
|Condition or disease||Intervention/treatment|
|Primary Ciliary Dyskinesia||Procedure: Chest physiotherapy|
Primary ciliary dyskinesia (PCD) is a rare disease, caused by congenital dysfunction of the motile cilia, located in the upper and lower respiratory tract, in the reproductive system and in the embryonal node. Ineffective ciliary beating results in disturbed mucociliary clearance, which is an important defense mechanism in the respiratory tract. It causes recurrent and chronic upper and lower respiratory tract infections, leading to reversible (mucus plugging) and irreversible lung damage (bronchiectasis, atelectasis, mucus plugging). Just like cystic fibrosis, it is characterized by obstructive lung disease, measured by spirometry.
Using Multiple Breath Washout measurements, it has been shown that peripheral airways disease is present in PCD. Probably, MBW parameters are already abnormal before forced expiratory volume in one second is abnormal.
The therapy for patients with PCD is mainly supportive: regular oral or intravenous antibiotics to treat airway infections and chest physiotherapy to actively increase mucociliary clearance. Chest physiotherapy has the objective to clear mucus from the lungs. Guidelines support the treatment of patients with PCD with chest physiotherapy. It is known that in patients with PCD, exercise has a more bronchodilating effect than the administration of salbutamol. However, no objective data describe the acute effect of chest physiotherapy on spirometry and MBW parameters. Moreover, short term effects of intervention on spirometry and MBW parameters can influence the interpretation of long-term evolution of these parameters.
In cystic fibrosis, one study has assessed the short-term influence of chest physiotherapy on lung function, measured by spirometry and MBW before and after chest physiotherapy. The authors found no significant influence of chest physiotherapy on spirometry parameters, nor on MBW parameters. Therefore, longitudinal interpretation can be performed irrespective of the timing of the lung function measurements. However, cystic fibrosis and PCD have a different pathophysiological mechanism with a more 'mechanical' disturbance of the mucociliary clearance in PCD, compared to a more 'viscous' disturbance of mucociliary clearance in CF. Therefore, the results in CF are not applicable to PCD. Even more, we hypothesize that chest physiotherapy will have a significant effect on lung function parameters (spirometry and MBW) in patients with PCD due to its external mechanical effect on mucus clearance.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Influence of Chest Physiotherapy on Lung Function Parameters in Primary Ciliary Dyskinesia|
|Anticipated Study Start Date :||October 2013|
|Primary Completion Date :||November 2017|
|Study Completion Date :||November 2017|
Experimental: chest physiotherapy
session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
Procedure: Chest physiotherapy
20 minutes of chest physiotherapy by physiotherapist
- Difference in FEV1 before and after treatment [ Time Frame: 30 minutes ]Lung function will be performed before a session of chest physiotherapy, and repeated 30 minutes after a chest physiotherapy session of 20 minutes with airway clearance techniques and use of PEP mask
- Difference in LCI before and after chest physiotherapy [ Time Frame: 30 minutes ]Multiple Breath Washout (MBW) will be performed before and 30 min after a session of chest physiotherapy. The difference in LCI (lung clearance index) will be used as secondary outcome.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01929356
|University Hospital Gasthuisberg Leuven|
|Leuven, Belgium, 3000|
|Principal Investigator:||Mieke Boon, MD||research fellow|